Somewhat Positive Press Coverage Somewhat Unlikely to Impact BioSpecifics Technologies (NASDAQ:BSTC) Stock Price

News articles about BioSpecifics Technologies (NASDAQ:BSTC) have trended somewhat positive this week, Accern reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. BioSpecifics Technologies earned a news sentiment score of 0.22 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 45.3192194017862 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Several research firms have weighed in on BSTC. Zacks Investment Research lowered BioSpecifics Technologies from a “buy” rating to a “hold” rating in a research report on Friday. HC Wainwright reaffirmed a “buy” rating on shares of BioSpecifics Technologies in a research report on Tuesday, December 26th. Finally, lowered their price target on BioSpecifics Technologies from $72.00 to $65.00 and set a “buy” rating on the stock in a research report on Wednesday, November 15th.

BioSpecifics Technologies (NASDAQ:BSTC) opened at $42.93 on Friday. BioSpecifics Technologies has a one year low of $41.95 and a one year high of $58.79. The company has a market capitalization of $310.35, a P/E ratio of 27.00 and a beta of 1.59.

BioSpecifics Technologies (NASDAQ:BSTC) last issued its earnings results on Friday, November 10th. The biopharmaceutical company reported $0.37 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.36 by $0.01. BioSpecifics Technologies had a return on equity of 19.11% and a net margin of 42.40%. The company had revenue of $6.52 million during the quarter, compared to the consensus estimate of $6.59 million. equities analysts expect that BioSpecifics Technologies will post 1.57 EPS for the current year.

WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact BioSpecifics Technologies (NASDAQ:BSTC) Stock Price” was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at

About BioSpecifics Technologies

BioSpecifics Technologies Corp. is a biopharmaceutical company involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. The Company has a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability company (Endo Global Ventures), an affiliate of Endo International plc (Endo), for injectable collagenase for marketed indications and indications in development.

Insider Buying and Selling by Quarter for BioSpecifics Technologies (NASDAQ:BSTC)

Receive News & Ratings for BioSpecifics Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSpecifics Technologies and related companies with's FREE daily email newsletter.

Leave a Reply